CN104350066B - 施马伦贝格病毒(sbv)疫苗、其制备方法及用途 - Google Patents

施马伦贝格病毒(sbv)疫苗、其制备方法及用途 Download PDF

Info

Publication number
CN104350066B
CN104350066B CN201380028863.3A CN201380028863A CN104350066B CN 104350066 B CN104350066 B CN 104350066B CN 201380028863 A CN201380028863 A CN 201380028863A CN 104350066 B CN104350066 B CN 104350066B
Authority
CN
China
Prior art keywords
sbv
vaccine composition
sequence
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380028863.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN104350066A (zh
Inventor
V·尼科林
K·施塔德勒
A·利舍夫斯基
A·布里克斯
J·P·克尼特尔
K·H·特普费尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica GmbH filed Critical Boehringer Ingelheim Vetmedica GmbH
Publication of CN104350066A publication Critical patent/CN104350066A/zh
Application granted granted Critical
Publication of CN104350066B publication Critical patent/CN104350066B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12061—Methods of inactivation or attenuation
    • C12N2760/12063—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201380028863.3A 2012-06-01 2013-05-29 施马伦贝格病毒(sbv)疫苗、其制备方法及用途 Active CN104350066B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12170631.1 2012-06-01
EP12170631 2012-06-01
EP13157875.9 2013-03-05
EP13157875 2013-03-05
PCT/US2013/043146 WO2013181270A1 (en) 2012-06-01 2013-05-29 Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof

Publications (2)

Publication Number Publication Date
CN104350066A CN104350066A (zh) 2015-02-11
CN104350066B true CN104350066B (zh) 2018-06-19

Family

ID=48607368

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380028863.3A Active CN104350066B (zh) 2012-06-01 2013-05-29 施马伦贝格病毒(sbv)疫苗、其制备方法及用途

Country Status (17)

Country Link
US (2) US9370562B2 (enExample)
EP (1) EP2855513B1 (enExample)
JP (1) JP6250649B2 (enExample)
CN (1) CN104350066B (enExample)
AR (1) AR091240A1 (enExample)
AU (1) AU2013267453C1 (enExample)
BR (1) BR112014029515A2 (enExample)
CA (1) CA2872961A1 (enExample)
DK (1) DK2855513T3 (enExample)
EA (1) EA034543B1 (enExample)
ES (1) ES2617351T3 (enExample)
IN (1) IN2014DN08927A (enExample)
MX (1) MX363044B (enExample)
PL (1) PL2855513T3 (enExample)
SG (1) SG11201407619SA (enExample)
UY (1) UY34840A (enExample)
WO (1) WO2013181270A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX363044B (es) 2012-06-01 2019-03-06 Boehringer Ingelheim Vetmedica Gmbh Vacuna de virus de schmallenberg (sbv), metodos de produccion y sus usos.
US9241960B2 (en) 2012-06-01 2016-01-26 Boehringer Ingelheim Vetmedica Gmbh Infectious Schmallenberg virus from cloned CDNAS and uses thereof
HK1216006A1 (zh) * 2013-03-12 2016-10-07 Boehringer Ingelheim Animal Health USA Inc. 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法
CN104232587B (zh) * 2014-09-02 2016-08-17 中国检验检疫科学研究院 稳定表达施马伦贝格病毒核衣壳蛋白的细胞系及其应用
CN120758460A (zh) * 2025-07-04 2025-10-10 中国兽医药品监察所 一种施马伦贝格病毒的假病毒及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0811736B2 (ja) * 1986-08-07 1996-02-07 財団法人化学及血清療法研究所 牛流行熱・イバラキ病・アカバネ病３種混合不活化ワクチン
GB9110808D0 (en) * 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
US6114108A (en) * 1995-08-29 2000-09-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of viral nucleic acids
US20080226682A1 (en) * 2007-03-13 2008-09-18 Peros Systems Technologies, Inc. Immunoactive Compositions for Improved Oral Delivery of Vaccines and Therapeutic Agents
EP2062594A1 (en) * 2007-11-21 2009-05-27 Wyeth Farma, S.A. Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
MX363044B (es) 2012-06-01 2019-03-06 Boehringer Ingelheim Vetmedica Gmbh Vacuna de virus de schmallenberg (sbv), metodos de produccion y sus usos.
US9241960B2 (en) 2012-06-01 2016-01-26 Boehringer Ingelheim Vetmedica Gmbh Infectious Schmallenberg virus from cloned CDNAS and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"A mutation ‘hot spot’ in the Schmallenberg virus M segment;Melina Fischer，et al.;《 Journal of General Virology》;20130630;第94卷;摘要，第1162-1163页和图1-2 *
In vivo and in vitro identification of a hypervariable region in Schmallenberg virus;Damien Coupeau, et al.;《Journal of General Virology》;20130630;第94卷;摘要，图1-3和第1173页左栏第2段 *
施马伦贝格病毒研究进展;吴晓东等;《病毒学报》;20141130;第30卷(第6期);第695页左栏第2段以及右栏第2段 *

Also Published As

Publication number Publication date
US9872897B2 (en) 2018-01-23
EA201401352A1 (ru) 2015-05-29
EP2855513A1 (en) 2015-04-08
US20130323277A1 (en) 2013-12-05
US20160250317A1 (en) 2016-09-01
US9370562B2 (en) 2016-06-21
AU2013267453A1 (en) 2014-11-13
IN2014DN08927A (enExample) 2015-05-22
BR112014029515A2 (pt) 2017-07-25
WO2013181270A1 (en) 2013-12-05
PL2855513T3 (pl) 2017-05-31
EA034543B1 (ru) 2020-02-19
DK2855513T3 (en) 2017-03-13
AU2013267453C1 (en) 2017-08-10
MX363044B (es) 2019-03-06
UY34840A (es) 2013-12-31
AR091240A1 (es) 2015-01-21
MX2014014521A (es) 2015-02-24
AU2013267453B2 (en) 2017-04-06
CA2872961A1 (en) 2013-12-05
SG11201407619SA (en) 2014-12-30
JP2015519367A (ja) 2015-07-09
CN104350066A (zh) 2015-02-11
ES2617351T3 (es) 2017-06-16
EP2855513B1 (en) 2016-12-07
JP6250649B2 (ja) 2017-12-20

Similar Documents

Publication Publication Date Title
US12290557B2 (en) Vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
ES2941967T3 (es) Vacuna contra el virus del Zika
US9872897B2 (en) Schmallenberg virus (SBV) vaccine, methods of production, and uses thereof
JP7587612B2 (ja) 改変ｐｅｄｖスパイクタンパク質
US10617752B2 (en) Inactivated canine influenza vaccines and methods of making and uses thereof
TW201701900A (zh) 二價豬流感病毒疫苗
TW202026010A (zh) 抗豬流行性下痢之鼻內載體疫苗
TW201828982A (zh) 抗豬小病毒及豬生殖與呼吸道症候群病毒之疫苗及其製造方法
US8361776B2 (en) Adaptation of Pitman Moore strain of rabies virus to primary chick embryo fibroblast cell cultures
HK40059925A (en) Novel vaccine compositions for porcine epidemic diarrhea virus
HK1104171A (en) Method of vaccination against testicular bvdv infection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant